These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27845591)

  • 21. Evolving molecules using multi-objective optimization: applying to ADME/Tox.
    Ekins S; Honeycutt JD; Metz JT
    Drug Discov Today; 2010 Jun; 15(11-12):451-60. PubMed ID: 20438859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of zebrafish in chemical biology and drug discovery.
    Das BC; McCormick L; Thapa P; Karki R; Evans T
    Future Med Chem; 2013 Nov; 5(17):2103-16. PubMed ID: 24215349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.
    Jones HM; Chen Y; Gibson C; Heimbach T; Parrott N; Peters SA; Snoeys J; Upreti VV; Zheng M; Hall SD
    Clin Pharmacol Ther; 2015 Mar; 97(3):247-62. PubMed ID: 25670209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systems pharmacology - Towards the modeling of network interactions.
    Danhof M
    Eur J Pharm Sci; 2016 Oct; 94():4-14. PubMed ID: 27131606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients.
    de Witte WE; Wong YC; Nederpelt I; Heitman LH; Danhof M; van der Graaf PH; Gilissen RA; de Lange EC
    Expert Opin Drug Discov; 2016; 11(1):45-63. PubMed ID: 26484747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using quantitative systems pharmacology for novel drug discovery.
    Pérez-Nueno VI
    Expert Opin Drug Discov; 2015 Dec; 10(12):1315-31. PubMed ID: 26328768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translational PK/PD modeling to increase probability of success in drug discovery and early development.
    Lavé T; Caruso A; Parrott N; Walz A
    Drug Discov Today Technol; 2016; 21-22():27-34. PubMed ID: 27978984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In silico tools used for compound selection during target-based drug discovery and development.
    Caldwell GW
    Expert Opin Drug Discov; 2015; 10(8):901-23. PubMed ID: 25952011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of the drug-target residence time model.
    Copeland RA
    Expert Opin Drug Discov; 2021 Dec; 16(12):1441-1451. PubMed ID: 34210223
    [No Abstract]   [Full Text] [Related]  

  • 30. An industrial perspective on contemporary applications of PBPK models in drug discovery and development.
    Smith BJ
    Biopharm Drug Dispos; 2012 Mar; 33(2):53-4. PubMed ID: 22407480
    [No Abstract]   [Full Text] [Related]  

  • 31. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lead PK commentary: predicting human pharmacokinetics.
    Rowland M; Benet LZ
    J Pharm Sci; 2011 Oct; 100(10):4047-9. PubMed ID: 21630278
    [No Abstract]   [Full Text] [Related]  

  • 33. The utility of target-based discovery.
    Croston GE
    Expert Opin Drug Discov; 2017 May; 12(5):427-429. PubMed ID: 28306350
    [No Abstract]   [Full Text] [Related]  

  • 34. Druggability Assessment of Targets Used in Kinetic Target-Guided Synthesis.
    Unver MY; Gierse RM; Ritchie H; Hirsch AKH
    J Med Chem; 2018 Nov; 61(21):9395-9409. PubMed ID: 29873484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies.
    Hu L; Hansen RJ
    J Pharm Sci; 2013 Sep; 102(9):2898-908. PubMed ID: 23508847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Applications of chemogenomic library screening in drug discovery.
    Jones LH; Bunnage ME
    Nat Rev Drug Discov; 2017 Apr; 16(4):285-296. PubMed ID: 28104905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Label-free MS imaging from drug discovery to preclinical development.
    Hochart G; Hamm G; Stauber J
    Bioanalysis; 2014 Oct; 6(20):2775-88. PubMed ID: 25413708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action.
    Vauquelin G
    Expert Opin Drug Discov; 2015 Oct; 10(10):1085-98. PubMed ID: 26165720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The power of enzyme kinetics in the drug development process.
    Samuele A; Crespan E; Garbelli A; Bavagnoli L; Maga G
    Curr Pharm Biotechnol; 2013; 14(5):551-60. PubMed ID: 22429137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What is the most important approach in current drug discovery: doing the right things or doing things right?
    Elebring T; Gill A; Plowright AT
    Drug Discov Today; 2012 Nov; 17(21-22):1166-9. PubMed ID: 22569181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.